We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Calling the impact of recent regulatory amendments to Canada's drug patent rules "unnecessary and costly to taxpayers," generic drug manufacturers led by the Canadian Generic Pharmaceutical Association (CGPA) are calling on a federal court to repeal modifications to federal regulations that provide brand name manufacturers with eight years of freedom from generic drug competition.
British advocacy group Oxfam has published a report saying that developing countries are still being denied cheaper life-saving drugs five years after the World Trade Organization (WTO) issued its Doha Declaration on the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement.
Torrent Pharmaceuticals, an India-based pharmaceutical company, announced it has received approval from the U.S. FDA for its active pharmaceutical ingredient (API) and formulations manufacturing facilities located in Chhatral, India.
Taro Pharmaceutical Industries, an Israel-based drugmaker, announced that its UK affiliate, Taro Pharmaceuticals, has been granted marketing authorization for generic etopan XL tablets, 600 mg, by the UK Medicines and Healthcare Products Regulatory Agency.
Biota has been informed that the Canadian government will increase the overall stockpile of antiviral drugs to 55 million courses and increase the proportion of Relenza (zanamivir) to 5.5 million courses.
UK drugmaker Shire has filed a patent infringement lawsuit against Andrx Pharmaceuticals and Watson Pharmaceuticals to stop the companies' from marketing a generic form of Shire's ADHD treatment drug, Adderall XR.
China Biopharma announced that through its subsidiary, Hainan CITIC Biopharmaceutical Development, it has completed the delivery of 1.5 million doses of flu vaccine in China.
The Global Fund to fight AIDS, Tuberculosis and Malaria has rejected Zimbabwe's sixth-round application for funding on undisclosed grounds, according to the Zimbabwe Standard.
A Quebec court has decided to authorize a limited class of Vioxx users in Quebec, declining to include in the class the vast majority of users who took the medicine and did not allege they were injured, according to Merck Frosst Canada, a subsidiary of Merck.
Sanofi-aventis has announced that Acomplia (rimonabant), recently approved in the European Union, has been granted reimbursement by the Pharmaceutical Benefits Board of Sweden for treatment of obese patients with a body mass index (BMI) of more than 35 kg/m2 or overweight patients with BMI of more than 28 kg/m2 and Type 2 diabetes or dyslipideamia.